Discover how Europe is transforming into a hotbed of innovation for chronic wound care through the breakthrough technology of cold plasma therapy. As the global focus on chronic wounds intensifies, European markets are witnessing a surge in new technologies that offer promising solutions. From smaller, portable devices to collaborative research efforts, this article highlights the rise of cold plasma therapy and its potential to revolutionize wound care. Download the article to further explore these, and other, key points:

• Europe's lower revenue levels for advanced wound therapies compared to the US present an opportunity for new technologies to thrive.
• Cold plasma therapy, utilizing low-temperature atmospheric pressure plasmas, demonstrates impressive benefits in treating chronic wounds, including bacterial inactivation and enhanced healing.
• Recent advancements have led to the development of smaller and more portable cold plasma devices, expanding treatment options beyond hospitals to ambulatory settings and even patients' homes.
• Swiss company ActivCell Group Ag, German companies neoplas med GmbH and Plasmacure BV and Dutch company Terraplasma Medical GmbH are among the pioneering companies offering innovative cold plasma devices.
• The future of cold plasma therapy depends on the willingness of companies to collaborate, navigate regulatory challenges, and establish a distinct market presence.
• While European advancements in cold plasma therapy are promising, the highly competitive US market remains a long-term goal for most companies, necessitating FDA approval and strategic partnerships.
• The rapid growth of topical oxygen therapy in the US, driven by initiatives like the Veterans Association and state-level Medicaid approvals, could potentially outpace European progress once FDA approval is obtained.

The full article delves into the transformative potential of cold plasma therapy in chronic wound care. Explore the advancements, collaborations and challenges that shape Europe's emerging market and its race against the US in revolutionizing wound treatment. Just click the button below to download the complete "EWMA 2023 - Cold Plasma Poised for Growth in Europe" article by Kris Flinn, SmartTRAK Senior Analyst - Wound.

With Smith+Nephew having dominated the wound debridement market for over a decade, SmartTRAK looks at how 2023 could be a year where we see the first signs of disruption.

The WW Wound Debridement Market is forecast to grow at a five-year CAGR of ~5.1%, according to SmartTRAK estimates. Although Smith+Nephew (SNN) has long dominated this market with more than 74% share, SmartTRAK believes 2023 could be a year of disruption in wound debridement as multiple players across a range of segments are poised to see financial returns after years of commercial progress. It is also worth noting that sharp debridement accounts for over half of the debridement procedures in the US, so the route to market growth is clear. 

SmartTRAK reports on the Wound Care Today 2023 Conference, where a number of challenges facing UK Advanced Dressings companies were on display

The UK Advanced Dressings Market is projected to grow at a five-year compound annual growth rate (CAGR) of +1.9%, according to SmartTRAK estimates. The UK market is growing slower than any of the nine advanced dressings markets that SmartTRAK reports on, including the markets for Total Europe (+3.2%) and Worldwide (+5.0%). Given that the number of chronic wounds is increasing annually and the rate of UK inflation is in the double digits, why is the growth of the UK market so poor compared to other markets?

Among the may topics covered in detail in this comprehensive look into Wound Care 2023 article are:

• Increasing Alignment of Advanced Dressing Portfolios
• Increased Presence of Premium Priced Therapies
• Digital Tools That Highlight Inappropriate Usage of Dressings
• The Hidden Impact of Hidradenitis Suppurativa

Any usage of advanced dressings to manage HS is vulnerable to switching to products tailored to the condition. Quantifying the size of this market niche is challenging but could be an increasing area of focus in ...

To download and read the complete "Wound Care Today 2023: Low Growth Impacting the UK Advanced Dressings Market" perspective article by Kris Flinn, SmartTRAK's Senior Analyst, Wound, just click the button below.

SmartTRAK interviews Advanced Oxygen Therapy Inc CEO and President Dr. Mike Griffiths to discuss how durable healing can improve health equality

Oxygen-based therapies have been used on chronic wounds for many years. In a recent article on the 2023 Oxygen and Energy Market, SmartTRAK expressed the view that the Topical Oxygen Therapy Market will grow at a significant rate and that Advanced Oxygen Therapy Inc* is likely to be the biggest driver of that growth. The Company has established a solid evidence base for its TWO2* system, a Topical Wound Oxygen therapy system which applies cyclical pressurized directly to a patient’s wound at home or in a healthcare facility. SmartTRAK talked with the company Medical Director, President and CEO, Dr. Mike Griffiths, about the journey that the company has been on so far, how durable healing and patient-led home care can reduce health inequalities and why the company has recently entered the Negative Pressure Wound Therapy (NPWT) Market.

To find out more about Advanced Oxygen Therapy Inc, click on the following video to listen to the recorded interview (27:56 min). A complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

With many of the “hard yards” already run, SmartTRAK believes that 2023 could be a promising year for the Oxygen and Energy segments of the Advanced Wound Care Market.

SmartTRAK estimates the 2021 WW Oxygen and Energy Market at just over $50.0MM. While this is not an insignificant amount, it trails far behind other Advanced Wound Care markets such as Negative Pressure Wound Therapy (NPWT) and Biologics. Last year, however, showed signs that clinicians are starting to realize the potential of these technologies. Here SmartTRAK looks at how some of the existing players in the markets for oxygen and energy therapies may show increased success in 2023 and why some of the leading wound care companies may soon be taking their first steps into these markets.

Among the many topics covered in this article are:

SmartTRAK highlights novel diagnostic devices for pressure ulcer (PU) prevention and interviews PU Sensor’s CEO Johannes Walfidsson at EPUAP 2022

According to SmartTRAK incidence and prevalence data*, there were over 10 million pressure ulcers in Europe in 2021, with four million being stage III to IV. This means that pressure ulcers account for around two-thirds of the total number of chronic wounds on the continent and almost half of the hard-to-heal wounds. Given these eye-opening statistics, it would be understandable to expect that the first European Pressure Ulcer Advisory Panel (EPUAP) Meeting in three years would indicate growing engagement in this area, both clinically and commercially. Unfortunately, on the evidence of the event in Prague, this wasn’t the case, with delegate numbers declining from previous years and a sparse exhibition hall missing many of the prominent wound care players. This begs the question; why isn’t there a greater focus on pressure ulcers and prevention? (Click to listen to SmartTRAK's interview with PU Sensor's CEO Johannes Walfidsson, "Advancing Risk Assessment for Pressure Ulcers." You can also download a complete transcript of the interview here)

Could biosensors and smart dressings be the final frontier in wound diagnostics? SmartTRAK explores the current progress of this market and how it could develop.

It has been 15 years since the World Union of Wound Healing Societies’ Initiative published a consensus document entitled “Diagnostics and Wounds.” Since then, the clinical practice around assessing and diagnosing wounds has not evolved at the same rate as that of treatments. At the same time, the need for improved wound diagnostics has never been greater given burgeoning chronic wound numbers and the continued shift of wound care services to the outpatient setting.

Could the next area of development be that of biosensors and smart dressings? SmartTRAK believes there is increasing evidence that this could be the case. In this article, we explore the developments that are taking place, how the identification of infection biomarkers may be lucrative and ways the market may change in the coming years.

Among the many topics discussed in this article are:

Increased wound prevalence meets new software and solutions at WCT 2022.

There was a positive energy in the room at the 5^th Wound Care Today (WCT) conference as industry and clinicians came together in Milton Keynes. COVID-19 infection rates remain high in the UK but this is not being reflected in hospitalizations or deaths, leading to a national determination to move forward without restrictions. The pandemic has, however, shaped the priorities of those present and in a range of discussions. SmartTRAK encountered a commercial eagerness to make up for lost time and a looming burden of chronic wounds.

The SmartTRAK team will be attending the upcoming European Wound Management Association (EWMA) event May 23-25 in Paris. We would love to schedule some time to meet and hear your perspectives and views and discuss how SmartTRAK can help you make more informed strategic business decisions.